HIV in Indian Women: Testing, ART, U=U and Prevention

• HIV is now a manageable chronic condition: one daily tablet (TLD) keeps the virus controlled and gives near-normal life expectancy.
• Testing is free, anonymous and confidential at over 20,000 NACO ICTCs; home self-test kits and private labs are also available.
• U=U is settled science: a person on effective ART with an undetectable viral load cannot pass HIV to a sexual partner.
• With the PPTCT programme, mother-to-baby transmission falls from up to 45% to under 1% — HIV-positive women can have HIV-negative babies.
• Prevention has expanded beyond condoms: PrEP (to prevent infection) and PEP (within 72 hours of exposure) are both free at NACO ART centres.
• HIV does not spread through food, hugs, toilets or casual contact — and the law protects you from discrimination and forced disclosure.

HIV (Human Immunodeficiency Virus) is a virus that infects CD4 T-cells — a type of immune cell — and slowly reduces their number over years. If left untreated, the immune system weakens to the point where unusual infections and cancers can take hold; this advanced stage is called AIDS (Acquired Immune Deficiency Syndrome). HIV-1 causes more than 95% of Indian infections; HIV-2 is less common and progresses more slowly.

Untreated HIV usually moves through three phases. A short flu-like illness (fever, swollen glands, rash, sore throat) can appear two to four weeks after infection and is often mistaken for an ordinary viral fever. A long phase with no symptoms follows — often eight to ten years — during which CD4 cells quietly fall. AIDS is the final stage, when the CD4 count drops below 200 and serious opportunistic infections such as tuberculosis, Pneumocystis pneumonia or cryptococcal meningitis appear.

Modern ART interrupts this whole journey. Started early and taken every day, it suppresses the virus to undetectable levels, lets CD4 cells recover, prevents AIDS, and restores a near-normal lifespan. The shift from a fatal illness to a one-tablet-a-day condition is one of medicine's great success stories.

In India around 2.4 million people live with HIV, and roughly 40% of them are women. Overall adult prevalence is low (about 0.2%), but it is higher in some states (parts of Andhra Pradesh, Karnataka, Maharashtra, Tamil Nadu, Nagaland, Manipur, Mizoram) and in certain groups. New infections have fallen sharply since the early-2000s peak thanks to NACO's condom promotion, community outreach, harm reduction and prevention-of-transmission programmes.

The Indian story for women is distinctive: a large share of female infections happen inside marriage, passed from a husband who acquired HIV elsewhere. Because many married women cannot easily ask a partner to use condoms, do not know about a partner's other contacts, or cannot test privately, this 'bridge' pattern remains one of the most important challenges in Indian women's HIV prevention.

HIV spreads through only three routes: sexual contact, blood-to-blood contact, and from mother to baby in pregnancy, delivery or breastfeeding. Sexual transmission is by far the most common route in India. Blood-borne spread happens mainly through shared needles in injecting drug use; transfusion-related HIV is now extremely rare because every unit of donated blood in India is screened.

The chance of catching HIV from a single sexual act is actually quite low, but it adds up over time and rises steeply in certain situations. Risk is higher when the partner's viral load is high (recent or untreated infection), when there is another STI present — genital ulcers from genital herpes or Syphilis in Women: Stages, Tests and Penicillin Cure can raise per-act risk several-fold — during menstruation, with rough or unprotected sex, and with receptive anal sex. This is one reason regular STI screening matters for sexually active women.

Without treatment, an HIV-positive mother has a 15-45% chance of passing the virus to her baby. With full prevention-of-transmission care, that falls to under 1% — covered in detail below.

Here is what HIV does NOT spread through, despite persistent myths: hugging, handshakes, sharing food, plates, utensils or drinks, swimming pools, public toilets, mosquito bites, sweat, tears, saliva (unless visibly bloody), sharing religious items, or any ordinary household or social contact. People living with HIV can share every part of family and community life safely. These myths do real harm — they fuel stigma and stop people from testing and getting care.

Biologically, women are roughly twice as likely as men to catch HIV during heterosexual sex. The lining of the vagina and cervix offers a larger surface area exposed to infected fluid, the cervical tissue of younger women is thinner and more vulnerable, and other untreated infections can break down the protective mucosal barrier.

Socially, the 'bridge' infection remains the defining Indian pattern: a married woman whose only partner is her husband becomes infected because he acquired HIV outside the marriage. She often has no sense of being at risk, little ability to insist on condoms, and may only be diagnosed when she is screened during pregnancy or when her husband falls ill.

Other factors compound this. Intimate partner violence both increases exposure (through forced sex) and removes a woman's ability to negotiate protection or testing — if this is your reality, support exists, including help for abuse and your legal options. Economic dependence, limited privacy, and patchy access to confidential services in rural areas all narrow women's choices. NACO programmes and women's networks work to address these structural barriers, alongside conversations about consent within marriage.

Younger women carry extra biological vulnerability through cervical ectopy (more exposed cervical tissue), often combined with new relationships and limited sexual-health information. This is why adolescent and young women are a global prevention priority — especially in India, where school-based sexuality education is still uneven.

Female sex workers face the highest occupational risk and have been central to NACO's targeted programmes. Prevalence in this group is around 1.6% and has fallen in recent years through condom promotion, peer education and STI services. They were among the first groups offered free PrEP in India from 2021.

HIV testing in India is easy to access, and there is an option for every privacy preference and budget. The most widely used route is NACO's network of more than 20,000 Integrated Counselling and Testing Centres (ICTCs) at district hospitals, primary health centres, medical colleges and antenatal clinics. ICTC testing is FREE, anonymous (no ID needed), confidential (results given only to you), and includes counselling before and after. A finger-prick rapid test gives a result in about 30 minutes.

Private labs add flexibility. SRL, Metropolis, Thyrocare, Dr Lal PathLabs and Apollo Diagnostics offer HIV rapid tests for roughly Rs 200-500, ELISA tests for Rs 400-1,000, fourth-generation combo tests (which detect infection earlier) for Rs 700-1,500, and viral load PCR (used after diagnosis to monitor treatment) for Rs 2,000-5,000. Home sample collection is widely available. Our guide to STI testing costs and anonymous clinics compares all of these pathways.

HIV self-test kits (oral swab or finger-prick) let you test completely privately at home for around Rs 300-700, with a result in about 20 minutes. Read the instructions carefully, and remember a reactive (positive) result is a screening result, not a diagnosis — always confirm it at an ICTC or clinic. NACO welcomes self-testing as a way to reach people who would not otherwise come forward.

Understanding the window period — the gap after exposure when a test can still read negative — matters. Rapid antibody tests usually turn positive within three to twelve weeks; a negative result is considered definitive at three months. Fourth-generation combo tests detect infection earlier (two to four weeks). Viral load PCR can detect HIV within one to two weeks but is reserved for special situations such as suspected acute infection or testing infants.

In practice: for routine screening with no specific worry, a rapid test is enough; after a possible exposure, repeat the test at three months to be sure; and if you have a flu-like illness after a high-risk exposure, a combo test plus viral load can catch infection early. NACO recommends yearly testing for sexually active adults with risk factors, testing for all pregnant women, and three-monthly testing for those on PrEP.

Today's standard Indian treatment is TLD — a single daily tablet combining tenofovir (TDF) 300 mg, lamivudine (3TC) 300 mg and dolutegravir (DTG) 50 mg. WHO recommended TLD as preferred first-line in 2018, and NACO adopted it as India's standard in 2020. It is well-tolerated, highly effective (over 90% of people who take it consistently reach an undetectable viral load within six months), has a high barrier to resistance, and needs no food restrictions.

NACO provides TLD — and every other ART regimen — FREE at more than 600 ART centres across India. Treatment is lifelong, but the cost to you is zero, including the medicines, the monitoring tests, and management of any side effects. Private ART is available (about Rs 1,000-3,000 a month for the same regimen) but the vast majority of Indian patients use the free government programme, one of the largest in the world.

Side effects of TLD are usually mild and settle within the first few weeks — nausea, mild headache, vivid dreams or trouble sleeping, and a little weight gain. Tenofovir carries a small, monitored risk to the kidneys and bones. Dolutegravir is well-tolerated and has replaced older drugs that caused more mood and sleep problems.

Pregnancy and TLD: an early signal from a 2018 Botswana study raised concern about neural tube defects in babies conceived on dolutegravir. Larger studies since then have shown the absolute risk is very small (about 0.3% versus a 0.1% background rate). WHO and NACO now recommend TLD as first-line for women of childbearing age, including those planning or in early pregnancy, with the benefits of viral suppression far outweighing this small risk.

Monitoring includes a CD4 count and a viral load test (the key marker — undetectable means treatment is working) roughly every six months, plus routine kidney, liver and blood tests. If the viral load is detectable, the team first reviews adherence, then considers resistance testing and second-line regimens, all available free through NACO.

The single most important advance in HIV care this decade is U=U — undetectable equals untransmittable. The finding is simple but profound: a person on effective ART whose viral load stays undetectable cannot pass HIV to a sexual partner. This is backed by large studies (HPTN 052, PARTNER, PARTNER 2, Opposites Attract) following thousands of mixed-status couples, with zero linked transmissions while the positive partner was virally suppressed.

What this means in everyday life is enormous. Someone with HIV on effective treatment can have a sexual relationship without using condoms specifically to prevent HIV (condoms may still be used for other STIs or contraception), can conceive children naturally, and no longer has to live in fear of infecting the people they love. 'Positive' no longer means 'infectious' for anyone on stable, effective treatment.

U=U is formally endorsed by NACO, WHO, UNAIDS, the CDC and the International AIDS Society. In India, this message is gradually reaching ART counselling, parent-to-child prevention discussions and community outreach through networks like INP+ (the Indian Network for People Living with HIV/AIDS). Shifting the message from 'you are dangerous, always use condoms' to 'stay undetectable, and you cannot transmit' takes time to spread.

For U=U to apply, the positive partner must be on ART, take it consistently, and have a documented undetectable viral load (typically under 200 copies/mL) — ideally sustained for at least six months — with ongoing monitoring. If doses are missed, a regimen is interrupted, or the viral load rises, U=U no longer applies until suppression is re-established. Couples relying on U=U should keep up regular viral load testing.

U=U has restored normal family planning for serodiscordant couples (one partner positive, one negative). Where conception once meant sperm washing or accepting some risk, a couple in which the positive partner is virally suppressed can now try for a baby naturally with essentially no transmission risk. PrEP for the HIV-negative partner adds extra reassurance if wanted, but is not strictly necessary once U=U is established.

NACO's Prevention of Parent-to-Child Transmission (PPTCT) programme is among the most successful in the world. It offers HIV testing to every pregnant woman at her first antenatal visit, starts triple-drug ART immediately for anyone who tests positive (whatever the CD4 count), plans the delivery to minimise the baby's exposure, gives the newborn preventive medicine, and supports safe infant feeding. With full implementation, mother-to-baby transmission drops to under 1%.

In pregnancy, the standard regimen is the same TLD tablet used outside pregnancy, started as soon as HIV is diagnosed and continued for life. The earlier dolutegravir concerns have been resolved by larger data, and WHO and NACO recommend TLD for all women, including in early pregnancy.

Delivery is managed on standard obstetric grounds. A woman with a sustained undetectable viral load can plan a normal vaginal birth — routine caesarean is no longer recommended as it once was. A planned caesarean before labour is reserved for the specific situation where the viral load is not suppressed near term (for example, a late diagnosis without enough time for ART to work). Broader STI screening and treatment in pregnancy is part of the same antenatal package.

Every baby born to an HIV-positive mother receives preventive antiretroviral medicine for four to six weeks. The baby is then tested by PCR at six weeks and six months, with a final antibody test at 18 months — the staggered schedule allows for the mother's antibodies, which linger in the baby and can confuse early antibody tests, to clear.

On feeding, the Indian recommendation is exclusive breastfeeding for six months while the mother stays on ART, rather than formula. With the mother's viral load suppressed, the substantial benefits of breastfeeding in Indian conditions — nutrition, immunity, lower infant mortality — outweigh the very small residual risk. Mixed feeding (some breast milk, some formula) is NOT advised because it carries a higher transmission risk than exclusive breastfeeding. After six months, complementary foods are added alongside breastfeeding up to two years, with ART continuing throughout.

HIV prevention today is a toolkit, not a single method: condoms plus biomedical prevention plus treatment-as-prevention plus STI care plus structural support. Together these sharply reduce risk for individuals and communities.

Pre-exposure prophylaxis (PrEP) is a daily tablet (tenofovir plus emtricitabine) taken by HIV-negative people to prevent infection — over 99% effective when taken consistently. NACO launched PrEP in India in 2021, initially for female sex workers, men who have sex with men, transgender people and serodiscordant couples, with access gradually widening. It is free at participating ART centres for eligible groups; private PrEP runs about Rs 1,500-3,000 a month. Our dedicated guide to PrEP for Indian women walks through eligibility, monitoring and how to start.

Post-exposure prophylaxis (PEP) is a 28-day course of antiretrovirals started within 72 hours of a possible exposure — condom failure with a positive or unknown partner, sexual assault, a needlestick injury, or shared injecting equipment. The standard Indian regimen is the same TLD combination, and PEP is free at NACO ART centres and many hospital emergency departments. The single most important thing about PEP is TIME: it must begin within 72 hours, ideally within 24, so go to the nearest emergency department or ART centre immediately rather than waiting. After a sexual assault, survivor care services can arrange PEP alongside other support.

Treatment as Prevention (TasP) is the population-level version of U=U: diagnosing everyone with HIV and getting them onto effective treatment prevents most onward transmission. This is the logic behind NACO's 95-95-95 targets — 95% of people with HIV diagnosed, 95% of them on ART, and 95% of those virally suppressed.

Condoms remain a low-cost, widely available foundation, cutting HIV transmission by around 80% with consistent correct use and protecting against most other STIs too. The female condom offers similar protection and puts control with the receptive partner — important for women who cannot rely on a partner using one. NACO distributes condoms free, and HLL's Nirodh brand sells them for a few rupees each.

Because people with HIV now live long lives, care has shifted from preventing AIDS to managing the everyday health of a chronic condition — heart health, blood sugar, kidney function, bones and certain cancers, which can affect HIV-positive people at slightly higher rates.

Routine monitoring includes a viral load test every six months (every three months in the first year), a CD4 count once or twice a year, and basic blood, kidney, liver, lipid and glucose checks. NACO ART centres provide all of these free.

Mental health deserves real attention. Depression and anxiety are more common in people living with HIV, partly from the stress of stigma and disclosure. ART centres increasingly offer counselling, and peer networks such as INP+ and positive women's networks provide support. If your mood, sleep or worry is affecting daily life, our guide to depression and anxiety in Indian women explains where to get help — and you can always ask your ART clinician for a referral.

Cervical screening is especially important for women with HIV, who have higher rates of persistent high-risk HPV and faster progression to disease. The usual advice is a Pap smear every six to twelve months in the first year after diagnosis, then every one to three years if stable; our walk-through of what your first Pap smear involves can make it less daunting. The HPV vaccine is recommended for HIV-positive women through age 26.

Other ongoing needs include TB screening at each visit (TB is the most common HIV-associated infection in India), hepatitis B and C testing, bone-density assessment after 40 (especially on tenofovir), and standard age-appropriate cancer screening. Increasingly, living with HIV is fully compatible with a normal lifespan and full participation in family, work and community life.

HIV stigma in India is still real, showing up as discrimination at work, in healthcare, in families and in schools. The HIV/AIDS Act 2017 prohibits discrimination based on HIV status and protects your confidentiality, though enforcement remains uneven.

Disclosure is a personal decision shaped by circumstances. Telling a current or future sexual partner is ethically (and in some interpretations, legally) expected, because they have a right to make informed choices about their own health. Beyond that — family, employers, friends — disclosure is entirely your choice, and there is no obligation to tell anyone you do not wish to.

Practical support helps. NACO counsellors are trained to support disclosure conversations and can role-play or sit with you. Positive networks offer peer experience; NACO regional offices, the NHRC and civil-society groups can help with discrimination. And U=U itself changes the conversation — being undetectable means you cannot transmit HIV to a partner, which should be part of any disclosure discussion.

Marriage and family are fully possible. Serodiscordant couples can have safe relationships and children through U=U; couples where both partners are positive have similar options; and many HIV-positive Indian couples have raised HIV-negative children through PPTCT.

Women face particular gendered challenges: a woman diagnosed at antenatal screening may be wrongly blamed even when her husband is the source, and some face violence or economic abandonment at disclosure. Support exists through NACO programmes, positive women's networks and legal aid. For the wider context of these conversations, see our guides on consent and marital sex in India and opening up conversations about marital rape and silence.

• National AIDS Control Organisation (NACO), Ministry of Health & Family Welfare, Government of India
• WHO — HIV and AIDS fact sheet
• WHO — Update of recommendations on first- and second-line antiretroviral regimens (dolutegravir/TLD)
• UNAIDS — Undetectable = Untransmittable (U=U) and treatment as prevention
• U.S. CDC — HIV Treatment as Prevention
• NACO — National Guidelines for HIV Care and Treatment / PPTCT